Lannett To Acquire Two Generic Pharmaceutical Products

(RTTNews) - Lannett Company, Inc. (LCI) said Wednesday that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg, upon the completion of a successful technical transfer.

The company did not disclose the name of the seller nor the financial terms of the deal.

Lannett said it expects to launch Estradiol Tablets within the next several months and Selegiline Hydrochloride Capsules sometime thereafter.

According to IMS, for the full year 2013 total sales of Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg at Average Wholesale Price were about $31.0 million and $8.5 million, respectively.

The reference listed drug manufacturer for Estradiol Tablets is Barr Laboratories, now a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (TEVA); Selegiline Hydrochloride Capsules 5 mg is the generic equivalent of Somerset Pharmaceuticals, Inc.'s Eldepryl.